 |
 |
 |
|
Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet
Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment
|
|
|
CROI: Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (02/27/15) oral talk by Paul Sax
CROI: Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy - (02/26/15) oral talk by David Wohl
CROI: Safety of Tenofovir Alafenamide in Renal Impairment - (02/27/15)
CROI: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) - (02/27/15) press release
CROI: Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study - - written by Mark Mascolini - (03/02/15)
CROI: CROI Big Stories: TAF safety/efficacy, new HIV ARTs attachment & maturation inhibitors; new HCV drugs study results in HIV/HCV coinfected - Harvoni, daclatasvir+sofosbuvir, Abbvie 3D - (Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin )
22nd Conference on Retroviruses and Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
-------------------
Reported by Jules Levin
CROI 205 Feb 23-26, Seattle, WA
H Kizito1, A Gaur2, W Prasitsuebsai3, N Rakhmanina4, E Lawson5, Y Shao5, S Bennett5, A Cheng5, E Quirk5
1 Joint Clinical Research Centre, Kampala, Uganda, 2 St Jude Children's Research Hospital, Memphis, TN, USA,
3 HIVNAT, Bangkok, Thailand, 4 Children's National Health System, Washington, DC, USA, 5 Gilead Sciences Inc., Foster City, CA, USA








What are z-score and T-score - http://en.wikipedia.org/wiki/Bone_density
Normal is a T-score of -1.0 or higher. Osteopenia is defined as between -1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.
Results are often reported in 3 terms:
1. Measured areal density in g cm-2
2. z-score, the number of standard deviations above or below the mean for the patient's age, sex and ethnicity
3. t-score, the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the patient


|
|
|
 |
 |
|
|